XBPXBP Global Holdings, Inc.
The schedule
- Thu15Oct
We project a formal conclusion or interim update regarding the ongoing strategic review by mid-October. Given the $474M enterprise value and massive $651M TTM revenue base, a take-private or asset divestiture could command a premium toward $3.50. However, if the process is abandoned, standalone dilution risks could crush shares down to $1.30.
- Thu11Feb
Assuming the strategic review yields no immediate buyout, XBP's Q3 2026 earnings will pivot back to fundamental cash preservation. The market will demand deep cost-cutting to stem the roughly $26M quarterly net loss rate. Stabilization could lift shares to $1.65, while further margin compression targets $1.00.
- Wed12May
The Q4 print will provide full-year 2026 performance and 2027 guidance. XBP's ability to transition its annualized revenue into positive EBITDA is the primary catalyst. Successful turnaround progress could push the stock to $1.35, while continued unprofitability risks a slide to $0.75.
- Fri14May
Q1 2027 earnings will test year-over-year comparables against the quarter when the strategic review was first initiated. Market patience for XBP's standalone strategy will be thin, requiring clear EPS improvement to hit $1.05, otherwise drifting to $0.55 on liquidity panic.
Past
- Thu13Aug
XBP's Q2 2026 earnings print will be heavily scrutinized for an update on the strategic alternatives process announced in May. With $197M in quarterly top-line revenue but net losses of $26.7M, the market requires evidence of a credible path to profitability or an outright sale. A lack of a concrete M&A or restructuring update could severely punish the stock, targeting $1.90.
- Fri15May
Actual outcome: Bear · $2.07 at outcome
Price reached or fell below bear floor ($1.90) at outcome date.